AR 882
Alternative Names: AR-882Latest Information Update: 22 Aug 2024
At a glance
- Originator Arthrosi Therapeutics Australia
- Developer Arthrosi Therapeutics; Arthrosi Therapeutics Australia
- Class Antigouts; Small molecules; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gout
Most Recent Events
- 19 Aug 2024 AR 882 receives Fast Track designation for Gout [PO,Capsule] in USA
- 27 Jun 2024 Arthrosi plans a pivotal phase III REDUCE 1 trial in Gout in 2H of 2024
- 12 Jun 2024 Efficacy and adverse events data from a phase II trial in Gout presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)